Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
United TherapeuticsUTHR -2.05%88 3-Year EBITDA Growth Rate is 21.20% as of Jun. 2026, which is 3% below its 10-year median of 21.95. GuruFocus rates UTHR with a GF Score™ of 88/100 and a GF Value™ of $426.85 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 809 Drug Manufacturers companies, United Therapeutics ranks better than 70.46% on this metric.
During the past 12 months, United Therapeutics's average EBITDA Per Share Growth Rate was 0.20% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 21.20% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 23.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of United Therapeutics was 128.00% per year. The lowest was -10.10% per year. And the median was 21.95% per year.
United Therapeutics (NAS:UTHR) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
United Therapeutics 3-Year EBITDA Growth Rate Related Terms
UTHR vs VTRS, NBIX, ZTS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, United Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
United Therapeutics 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, United Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where United Therapeutics's 3-Year EBITDA Growth Rate falls into.
United Therapeutics 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 21.20% mean?
United Therapeutics (UTHR) has a 3-Year EBITDA Growth Rate of 21.20% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for United Therapeutics and its competitors. This is near median its historical median of 21.95. According to the industry distribution chart, United Therapeutics ranks #239 out of 809 companies in the Drug Manufacturers industry, placing it in the top 29.5%.
Is United Therapeutics' 3-Year EBITDA Growth Rate too high?
United Therapeutics' current 3-Year EBITDA Growth Rate of 21.20% is near median its 10-year median of 21.95. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. United Therapeutics' value of 21.20% is 138.2% above this industry median. Based on the distribution chart, United Therapeutics ranks #239 out of 809 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, United Therapeutics has a GF Score™ of 88/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does United Therapeutics' 3-Year EBITDA Growth Rate compare to VTRS and NBIX?
According to the Drug Manufacturers industry distribution chart, United Therapeutics ranks #239 out of 809 companies for 3-Year EBITDA Growth Rate. This puts United Therapeutics in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.90. United Therapeutics' value of 21.20% is 138.2% above this benchmark. While the company's 10-year median is 21.95 vs. the industry median of 8.90, United Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. United Therapeutics's current 3-Year EBITDA Growth Rate of 21.20% is 138.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for United Therapeutics and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. United Therapeutics's current 3-Year EBITDA Growth Rate is 21.20%, which is near median its own 10-year median of 21.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is United Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, United Therapeutics (UTHR) is currently considered Modestly Overvalued. The stock's GF Value™ is $426.85, compared to a current price of $501.27 — trading 17.4% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 21.20%, which is near median its 10-year median of 21.95 and 138.2% above the Drug Manufacturers industry median of 8.90. United Therapeutics' overall GF Score™ is 88/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For United Therapeutics (UTHR), the current 3-Year EBITDA Growth Rate is 21.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is United Therapeutics (UTHR) Overvalued in 2026?
Based on GuruFocus' analysis, United Therapeutics stock appears to be overvalued.
The current stock price of $501.27 is trading 17.4% above its estimated GF Value™ of $426.85.
GuruFocus considers United Therapeutics to be Modestly Overvalued.
Key valuation signals for UTHR:
3-Year EBITDA Growth Rate: 21.20% (near median its 10-year median of 21.95)
GF Value™: $426.85 vs. price of $501.27 (17.4% above fair value)
Industry Position: 138.2% above the Drug Manufacturers median (#239 of 809)
No single metric tells the full story. See the UTHR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
88GF Score
Get the complete analysis for UTHR
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
UTHR has been successfully added to your 
